Abemaciclib

CHEMBL3301610 Phase 4 अनुमोदित Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
506.6 g/mol
LogP
3.8
Phase
4

An oral targeted cancer therapy that blocks proteins called CDK4 and CDK6, which cancer cells rely on to divide and multiply uncontrollably. It is primarily used in combination with hormonal therapies to treat certain types of hormone receptor-positive, HER2-negative breast cancer. Common side effects include diarrhea, which should be treated promptly, as well as low white blood cell counts that increase infection risk.

आणविक भार

506.6000 g/mol

LogP

3.80

TPSA

75.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

क्रिया का तंत्र

Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

2D संरचना

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1

InChI

InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)

Molecular Formula

C27H32F2N8

HBD / HBA

1 / 9

घूर्णनीय बंधन

7

भारी परमाणु

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

An oral targeted cancer therapy that blocks proteins called CDK4 and CDK6, which cancer cells rely on to divide and multiply uncontrollably. It is primarily used in combination with hormonal therapies to treat certain types of hormone receptor-positive, HER2-negative breast cancer. Common side effects include diarrhea, which should be treated promptly, as well as low white blood cell counts that increase infection risk.

Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.

Yes, Abemaciclib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301610. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 46220502. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.